Differential efficacy between stenting and plain balloon angioplasty for femoropopliteal disease with or without total occlusion
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Whether the presence of chronic total occlusion (CTO) affects patency after stenting in femoropopliteal lesions is unknown. We determined the effects of plain balloon angioplasty (POBA) in comparison with those of stenting on patency for femoropopliteal CTO and stenosis (non-CTO). Methods: We analyzed data from the Korean Vascular Intervention Society Endovascular Therapy in Lower-Limb Artery Diseases Registry, a multicenter cohort of patients with lower extremity peripheral arterial disease. Data from 1,329 patients and 1558 limbs treated with endovascular intervention for at least one femoropopliteal lesion were evaluated. Results: Among the 1,558 limbs, 345, 432, 275, and 506 were in the non-CTO-POBA, non-CTO-stent, CTO-POBA, and CTO-stent groups, respectively. During follow-up, loss of clinical primary patency, a composite of freedom from restenosis or clinically driven target lesion revascularization, occurred in 65 (18.8%), 68 (15.7%), 62 (22.5%), and 113 limbs (22.3%) in the non-CTO-POBA, non-CTO-stent, CTO-POBA, and CTO-stent groups, respectively. The patients in the non-CTOstent group showed a significantly better clinical primary patency than those in the no-CTO-POBA group, whereas those in the CTO-stent and CTO-POBA groups showed no significant differences. After inverse probability of treatment weighting to balance the differences among covariates between the non-CTOstent and non-CTO-POBA groups, the non-CTO-stent group still showed superior clinical primary patency as compared with the non-CTO-POBA group. Conclusions: In the patients with femoropopliteal stenosis without CTO, stenting resulted in better clinical outcomes than balloon angioplasty. The presence of CTO in the femoropopliteal lesion should be considered when selecting a suitable device for performing endovascular procedures.
Abstract
Background/Aims: Whether the presence of chronic total occlusion (CTO) affects patency after stenting in femoropopliteal lesions is unknown. We determined the effects of plain balloon angioplasty (POBA) in comparison with those of stenting on patency for femoropopliteal CTO and stenosis (non-CTO). Methods: We analyzed data from the Korean Vascular Intervention Society Endovascular Therapy in Lower-Limb Artery Diseases Registry, a multicenter cohort of patients with lower extremity peripheral arterial disease. Data from 1,329 patients and 1558 limbs treated with endovascular intervention for at least one femoropopliteal lesion were evaluated. Results: Among the 1,558 limbs, 345, 432, 275, and 506 were in the non-CTO-POBA, non-CTO-stent, CTO-POBA, and CTO-stent groups, respectively. During follow-up, loss of clinical primary patency, a composite of freedom from restenosis or clinically driven target lesion revascularization, occurred in 65 (18.8%), 68 (15.7%), 62 (22.5%), and 113 limbs (22.3%) in the non-CTO-POBA, non-CTO-stent, CTO-POBA, and CTO-stent groups, respectively. The patients in the non-CTOstent group showed a significantly better clinical primary patency than those in the no-CTO-POBA group, whereas those in the CTO-stent and CTO-POBA groups showed no significant differences. After inverse probability of treatment weighting to balance the differences among covariates between the non-CTOstent and non-CTO-POBA groups, the non-CTO-stent group still showed superior clinical primary patency as compared with the non-CTO-POBA group. Conclusions: In the patients with femoropopliteal stenosis without CTO, stenting resulted in better clinical outcomes than balloon angioplasty. The presence of CTO in the femoropopliteal lesion should be considered when selecting a suitable device for performing endovascular procedures.
참고문헌 (21)
- Aboyans V, "2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)", Eur Heart J, 39, pp.763~816 (2018)
- Mwipatayi BP, "Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease : a meta-analysis", J Vasc Surg, 47, pp.461~469 (2008)
- Schillinger M, "Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting", Circulation, 115, pp.2745~2749 (2007)
- Nguyen BN, "Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent", J Vasc Surg, 54, pp.1051~1057 (2011)
- 고영국, "Baseline Characteristics of a Retrospective Patient Cohort in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry", Korean Circulation Journal, 47(4), pp.469~476 (2017), 대한심장학회
- Rutherford RB, "Recommended standards for reports dealing with lower extremity ischemia : revised version", J Vasc Surg, 26, pp.517~538 (1997)
- Norgren L, "Inter-society consensus for the management of peripheral arterial disease(TASC II)", J Vasc Surg, 45(Suppl S), pp.S5~S67 (2007)
- Dos Santos VP, "Risk factors for primary major amputation in diabetic patients", Sao Paulo Med J, 124, pp.66~70 (2006)
- Wang C, "Reducing major lower extremity amputations after the introduction of a multidisciplinary team in patient with diabetes foot ulcer", BMC Endocr Disord, 16, pp.38~ (2016)
- Cutlip DE, "Clinical end points in coronary stent trials : a case for standardized definitions", Circulation, 115, pp.2344~2351 (2007)
- Schillinger M, "Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery", N Engl J Med, 354, pp.1879~1888 (2006)
- Laird JR, "Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery : twelve-month results from the RESILIENT randomized trial", Circ Cardiovasc Interv, 3, pp.267~276 (2010)
- Krankenberg H, "Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST)", Circulation, 116, pp.285~292 (2007)
- Chowdhury MM, "Angioplasty versus bare metal stenting for superficial femoral artery lesions", Cochrane Database Syst Rev, 6, pp.CD006767~ (2014)
- Gallagher KA, "Endovascular management as first therapy for chronic total occlusion of the lower extremity arteries : comparison of balloon angioplasty, stenting, and directional atherectomy", J Endovasc Ther, 18, pp.624~637 (2011)
- Schmieder GC, "Selective stenting in subintimal angioplasty : analysis of primary stent outcomes", J Vasc Surg, 48, pp.1175~1180 (2008)
- Zeller T, "Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents", JACC Cardiovasc Interv, 6, pp.274~281 (2013)
- Werk M, "Inhibition of restenosis in femoropopliteal arteries : paclitaxel-coated versus uncoated balloon : femoral paclitaxel randomized pilot trial", Circulation, 118, pp.1358~1365 (2008)
- Liistro F, "Drug-eluting balloon in peripheral intervention for the superficial femoral artery:the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery)", JACC Cardiovasc Interv, 6, pp.1295~1302 (2013)
- Tepe G, "Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN-.PACT SFA randomized trial", Circulation, 131, pp.495~502 (2015)
- Vent PA, "Bare metal versus paclitaxel-eluting stents for long femoropopliteal lesions:prospective cohorts comparison using a propensity score-matched analysis", Ann Vasc Surg, 43, pp.166~175 (2017)